Key Account Manager, aT1D; Western

Reference Number: R2872862

Position Title: Key Account Manager, aT1D

Department: National Ecosystem

Location: British Columbia (Field based)

We’re an R&D-driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. Our deep understanding of the immune system – and innovative pipeline – enables us to invent medicines and vaccines that treat and protect millions of people around the world. Together, we chase the miracles of science to improve people’s lives.

Join the team transforming how healthcare is delivered for chronic and specialty conditions worldwide. In General Medicines, you’ll help drive meaningful outcomes in diabetes, transplant, and immunology - with the scale and urgency patients deserve.

Type 1 diabetes care is entering a new era. We now know that type 1 diabetes is an autoimmune disease that Progresses through identifiable stages before symptoms appear, and that its onset can be delayed when it is detected early. With a first-in-class therapy, Sanofi is building a new paradigm of care in Canada: identifying people at risk, staging and monitoring them, and treating before clinical diagnosis.

Much of the pathway this requires, from screening and referral to treatment and infusion capacity, does not yet exist at scale and is being built now, account by account.

The aT1D Key Account Manager is a full-time position within the Gen Med aT1D portfolio within a rapidly evolving Type 1 diabetes marketplace. Focused on the aT1D ecosystem, you will call on endocrinologists, internists, diabetes educators, primary care physicians & pharmacists.

You will develop and implement integrated business/account plans that deliver the budgeted revenue and proper utilization of resources, in major key accounts, including advocacy development, access, budget management and promotional material.

• Segmenting accounts (e.g., Centers of Excellence, referring centers, or other key accounts in the Autoimmune Type 1 diabetes local care pathway) and developing in-depth knowledge of each identified key account including strategic goals, value drivers, relevant business metrics, and unique emerging needs.
• Understanding key accounts’ critical stakeholders (e.g., endocrinology / immunology ‘C-suite’ executives and key decision makers), their roles, org structure and how they influence each other in to ensure account/departmental coordination.
• Developing understanding of target accounts (e.g., Centers of Excellence or other key accounts in the Autoimmune Type 1 diabetes local care pathway) functioning and existing screening/infusion infrastructure to identify operational barriers that could prevent patients from accessing screening or treatment administration.
• Developing strategic account plans including prioritization, based on identified barriers to address opportunities. Co-creating solutions with accounts’ key decision-makers to remove operational barriers and supporting screening and monitoring initiatives.
• Collaborating to establish screening and infusion infrastructure beyond key Centers of Excellence, (e.g., specialized sites to develop home infusion solutions)
• Collaborate with the Ecosystem Manager, referring centres and treating specialists to ensure people identified through screening are referred and assessed in a timely manner, before progression to Stage 3.
• Engaging with accounts’ key stakeholders to convey a compelling narrative on disease awareness, screening, treatment options and tailoring engagement to the stakeholders’ level of maturity.
• Build conviction among endocrinologists in the clinical rationale for early intervention and in the treatment’s indication, efficacy and safety profile, translating it into…